Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients’ groups, and clinician specialty societies to help develop a “value framework”.

Payers in the US do not embrace a single, dominant method for determining the value of new technologies. With this mind, Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients’ groups, and clinician specialty societies to help develop a “value framework” to guide the assessment of drugs and devices in the US. In this Briefing, based on an OHE lunchtime seminar, he presents an early draft version of this framework as a method for integrating elements of cost-effectiveness and affordability.